ReviewBiochimica et biophysica acta. Molecular basis of disease2020
SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets.
Review in Biochimica et biophysica acta. Molecular basis of disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 94 citations in OpenAlex.
- Practical Challenges in the Diagnosis of SARS-CoV-2 Infection in Children.Nursing reports (Pavia, Italy) · 2025Article
- Bioactive Molecules from Tropical American Plants: Potential Anti-Inflammatory Agents for Cytokine Storm Management.Molecules (Basel, Switzerland) · 2025Review
- Neuroimaging markers of cognitive fatigue in individuals with post-acute sequelae of SARS-CoV-2 infection.Brain and cognition · 2025Article
- Orthotopic Liver Transplantation of a SARS-CoV-2 Negative Recipient from a Positive Donor: The Border between Uncertainty and Necessity in a Pandemic Era- Case Report and Overview of the Literature.Medicina (Kaunas, Lithuania) · 2023Review
- Global trends in COVID-19 Alzheimer's related research: a bibliometric analysis.Frontiers in neurology · 2023Article
- A review on the impacts of COVID-19 on the auditory system: Implications for public health promotion research.Health promotion perspectives · 2023Review
- Coronavirus disease 2019 and acute cerebrovascular events: a comprehensive overview.Frontiers in neurology · 2023Review
- Sudden Sensorineural Hearing Loss in the COVID-19 Pandemic: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
- Cerebral microvascular complications associated with SARS-CoV-2 infection: How did it occur and how should it be treated?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Virus blocking textile for SARS-CoV-2 using human body triboelectric energy harvesting.Cell reports. Physical science · 2022Article
- Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting.International journal of molecular sciences · 2022Review
- Intestinal viral infections of nSARS-CoV2 in the Indian community: Risk of virus spread in India.Journal of medical virology · 2022Review
- Molecular Modeling Targeting Transmembrane Serine Protease 2 (TMPRSS2) as an Alternative Drug Target Against Coronaviruses.Current drug targets · 2022Review
- Research Progress on the Role of Microglia Membrane Proteins or Receptors in Neuroinflammation and Degeneration.Frontiers in cellular neuroscience · 2022Review
- Possible therapeutic targets and promising drugs based on unsymmetrical hetaryl-substituted porphyrins to combat SARS-CoV-2.Journal of pharmaceutical analysis · 2021Article
- Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics.Life (Basel, Switzerland) · 2021Review
- Exploration ofChemical physics · 2021Article
- GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Sudden sensorineural hearing loss in a post-COVID-19 patient.Clinical case reports · 2021Article
- Analytical and Clinical Performance of Droplet Digital PCR in the Detection and Quantification of SARS-CoV-2.Molecular diagnosis & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
The novel Coronavirus disease of 2019 (nCOV-19) is a viral outbreak noted first in Wuhan, China. This disease is caused by Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2. In the past, other members of the coronavirus family, such as SARS and Middle East Respiratory Syndrome (MERS), have made an impact in China and the Arabian peninsula respectively. Both SARS and COVID-19 share similar symptoms such as fever, cough, and difficulty in breathing that can become fatal in later stages. However, SARS and MERS infections were epidemic diseases constrained to limited regions. By March 2020 the SARS-CoV-2 had spread across the globe and on March 11th, 2020 the World Health Organization (WHO) declared COVID-19 as pandemic disease. In severe SARS-CoV-2 infection, many patients succumbed to pneumonia. Higher rates of deaths were seen in older patients who had co-morbidities such as diabetes mellitus, hypertension, cardiovascular disease (CVD), and dementia. In this review paper, we discuss the effect of SARS-CoV-2 on CNS diseases, such as Alzheimer's-like dementia, and diabetes mellitus. We also focus on the virus genome, pathophysiology, theranostics, and autophagy mechanisms. We will assess the multiorgan failure reported in advanced stages of SARS-CoV-2 infection. Our paper will provide mechanistic clues and therapeutic targets for physicians and investigators to combat COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.